# RDEA3170 Tablet and Capsule Bioavailability Study

> **NCT02448368** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** RDEA3170,10 mg
- **DRUG:** RDEA3170, 2.5 mg
- **DRUG:** RDEA3170, 5 mg
- **DRUG:** RDEA3170, 10 mg
- **DRUG:** RDEA3170, 2.5 mg

## Key facts

- **NCT ID:** NCT02448368
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2015-06-26
- **Final completion:** 2016-01-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448368, "RDEA3170 Tablet and Capsule Bioavailability Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02448368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*